ascendis pharma glp-1 receptor agonists weight management diabetes treatments Agonists: Revolutionizing the Treatment of Obesity, but Are They Enough? - Eric Velazquez, MD - Bariatric Surgeon - Longstreet Clinic Center for ascendis pharma glp-1 receptor agonist
Description
Zhao, H., Wang, L., Wei, R., Xiu, D., Tao, M., Ke, J., Liu, Y., Yang, J., & Hong, T

Qsymia is taken orally

About 50,000 of Blue Crosss 3 million members were taking GLP-1s as of Jan

11 , e70076 (2025)
In addition, the gut-derived metabolite imidazole propionate has been shown to drive -synuclein pathology in preclinical and patient-derived PD models, providing a direct link between dysbiosis and -synuclein aggregation (103)

The primary one is competition from other GLP-1 drugs, especially from Eli Lillys Mounjaro (tirzepatide), which has shown greater efficacy in weight loss and diabetes control
